Commonwealth Equity Services
TOVX icon

Commonwealth Equity Services’s Theriva Biologics TOVX Stock Holding History

Commonwealth Equity Services’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1
Closed -$3K – 2862
2018
Q2 		$3K Hold
1
– – ﹤0.01% 2763
2018
Q1 		$3K Hold
1
– – ﹤0.01% 2707
2017
Q4 		$6K Sell
1
-1
-50% -$6.25K ﹤0.01% 2678
2017
Q3 		$14K Hold
2
– – ﹤0.01% 2540
2017
Q2 		$8K Buy
2
+1
+100% +$4.98K ﹤0.01% 2512
2017
Q1 		$7K Hold
1
– – ﹤0.01% 2410
2016
Q4 		$8K Buy
+1
New +$10.3K ﹤0.01% 2311

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Commonwealth Equity Services's TOVX Position: Q3 2018 in Review

Commonwealth Equity Services sold out of Theriva Biologics (TOVX) in Q3 2018, closing a stake of 1 share — an estimated $3K sold.

Commonwealth Equity Services first reported a position in TOVX in Q4 2016 and held it in 7 quarters. The position peaked at $14K in Q3 2017. 22 funds tracked by Wall St. Rank hold TOVX as of Q3 2018.

  • Commonwealth Equity Services reported no remaining Theriva Biologics position as of Q3 2018 after selling out during the quarter.
  • Commonwealth Equity Services sold 1 Theriva Biologics share in Q3 2018, an estimated $3K.
  • Commonwealth Equity Services first reported a position in Theriva Biologics in Q4 2016 and held it in 7 quarters.
  • Commonwealth Equity Services's Theriva Biologics position peaked at $14K in Q3 2017.
  • 22 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2018.

Based on Commonwealth Equity Services's 13F filing for Q3 2018, filed 6 Nov 2018.